A neighbor brought up the vaccine question, and this is what I sent her.
Two doctors filed an emergency Stay of Action with the European Medicines Agency, but it was denied. They are Dr. Wolfgang Wodarg and Dr. Michael Yeadon, the former head of Pfizer drug research in the UK.
https://healthimpactnews.com/wp-content/uploads/sites/2/2020/12/Wodarg_Yeadon_EMA_Petition_Pfizer_Trial_FINAL_01DEC2020_EN_unsigned_with_Exhibits.pdf
Their point is that answers to these questions and potential problems have not been offered by Pfizer. I’m not opposed to a vaccine if it safe and effective, but I believe these goals have yet to be proven.
Also, after getting approval in the UK, the Pfizer CEO said -
In a Thursday night interview with NBC, the CEO expressed confidence in the ability “to send vaccines within 24 hours basically [anywhere] in the U.S.” after receiving emergency use authorization from the Food and Drug Administration, but he remains unconfident in the vaccine’s ability to be a silver bullet against people carrying and transmitting COVID-19.
“Even though I’ve had the protection, am I still able to transmit it to other people?” NBC’s Lester Holt asked, to which Bourla responded: "I think this is something that needs to be examined. We are not certain about that right now.”
https://www.zerohedge.com/medical/pfizer-ceo-not-certain-vaccine-will-stop-people-spreading-covid-19
The filing is a lot to read and some of the technical terms are above me, but I got the gist of it, and there are several very important points
Page 4 Item 8
This speaks to the cytokine storms that some people experienced.
"In some viruses, if a person harbors a non-neutralizing antibody to the virus, a subsequent infection by the virus can cause that person to elicit a more severe reaction to the virus due to the presence of the non-neutralizing antibody. This is not true for all viruses, only particular ones. This is called Antibody Dependent Enhancement (ADE), and is a common problem with Dengue Virus, Ebola Virus, HIV, RSV, and the family of coronaviruses. In fact, this problem of ADE is a major reason why many previous vaccine trials for other coronaviruses failed."
Page 5 Item 9
Questions about trial design - no info on does vaccine prevent severe symptoms such as hospitalization or does it prevent spread. The Pfizer CEO already said they need to look into the spread issue. My question is the same as noted in the filing - then why take it at all if no one knows if it really works.
Page 5 Item 10
Vaccine uses polyethylene glycol to which many people produce antibodies, which then can potentially reduce the effectiveness of the vaccine or lead to a severe reaction.
Vaccine includes mNeonGreen, which is a bioluminescent material from a marine animal. Exactly why is that needed?
Page 5 Item 11
Vaccine includes humoral antibodies, which are thought to be effective against the spike proteins of the cover virus. However - and this is a big one - there are no answers as to whether this will also affect a similar process in the formulation of the placenta, thus making women infertile, which could affect girls and teens getting the vaccine, too.
Here is one more piece of info - in 1986, Congress passed the National Childhood Vaccine Injury Act (NCVIA). Drug companies were experiencing multiple lawsuits over vaccine related injuries and slowed or stopped the production of some vaccines. This act took the responsibility for safety from the companies and put it in the National Vaccine Program Office. This government group considers Phase 4 testing to be when the vaccine is licensed for the public, and then they look at long-term problems.
